title: Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study.
abstract: OBJECTIVE
  To determine the rate of Helicobacter pylori eradication following bismuth-based triple therapy with colloidal bismuth subcitrate, tetracycline hydrochloride and metronidazole.
  
  
  METHODS
  One hundred and eleven patients were randomly assigned, in a two to one ratio, to colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid (Gastrostat), or matching placebo tablets and capsules for 14 days. Presence or absence of H pylori was documented by histology at entry and at least 28 days after treatment. Patients had dyspeptic symptoms with or without a history of peptic ulcer. Patients with any previous attempt(s) at eradication of H pylori, who used bismuth, antibiotics, H2 receptor antagonists or proton pump inhibitors in the previous four weeks were excluded.
  
  
  RESULTS
  Fifty-three of 59 (90%) patients on bismuth-based treatment and only one of 35 (3%) on placebo achieved eradication by per protocol analysis. Fifty-three of 65 (82%) patients on bismuth-based treatment achieved eradication, while only two of 34 (5%) achieved eradication on placebo by intention to treat analysis. Eradication rates for bismuth-based treatment across sites ranged from 83% to 100%. Only two patients in the bismuth-based treatment group (4%) and one in the placebo group (3%) discontinued treatment because of adverse events.
  
  
  CONCLUSIONS
  Colloidal bismuth subcitrate plus metronidazole plus tetracycline, given in the doses studied for 14 days, is safe and highly effective against H pylori infection and would be appropriate as a first-line therapy for eradication.
authors.affiliation: Dalhousie University, Halifax, Canada. gisxm@qe2-hsc.ns.ca
authors.forename: S
authors.initials: S
authors.lastname: Veldhuyzen Van Zanten
authors.forename: A
authors.initials: A
authors.lastname: Farley
authors.forename: N
authors.initials: N
authors.lastname: Marcon
authors.forename: R
authors.initials: R
authors.lastname: Lahaie
authors.forename: A
authors.initials: A
authors.lastname: Archambault
authors.forename: R
authors.initials: R
authors.lastname: Hunt
authors.forename: R
authors.initials: R
authors.lastname: Bailey
authors.forename: D
authors.initials: D
authors.lastname: Owen
authors.forename: J
authors.initials: J
authors.lastname: Spénard
authors.forename: A
authors.initials: A
authors.lastname: Stiglick
authors.forename: N
authors.initials: N
authors.lastname: Aimola
authors.forename: P
authors.initials: P
authors.lastname: Colin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000863:Antacids / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D013752:Tetracycline / Q000627:therapeutic use*
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D008795:Metronidazole; D013752:Tetracycline; D001729:Bismuth